Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib
Ilario Giovanni Rapposelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Margherita Rimini(Vita-Salute San Raffaele University), Norio Itokawa(Chiba Hokusou Hospital), Hironori Koga(Kurume University), Takuji Torimura(Omuta hospital), Joji Tani(Kagawa University), Kazuhito Kawata(Hamamatsu University School of Medicine), Emiliano Tamburini(Ospedale Infermi di Rimini), Hiroshi Shibata(Social Insurance Saitama Chuo Hospital), Kazuya Kariyama(Okayama Prefecture), Hironori Ochi, Giuseppe Cabibbo(Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo), Hidenori Toyoda(Ogaki Municipal Hospital), Kazuhiro Nouso(Okayama Prefecture), Fabio Piscaglia(Azienda USL di Bologna), Yoichi Hiasa(Ehime University Hospital), Shigeo Shimose(Kurume University), Raffaella Tortora, Atsushi Hiraoka(Ehime Prefectural Central Hospital), Takashi Kumada(Gifu Kyoritsu University), Shinya Fukunishi(Osaka Medical and Pharmaceutical University), Tomomi Okubo(Nippon Medical School), Valentina Burgio(Vita-Salute San Raffaele University), Takuya Nagano(Kagawa Prefectural Central Hospital), Claudia Campani(Inserm), Ei Itobayashi(Asahi General Hospital), Sara Lonardi(Istituto Oncologico Veneto), Gianluca Masi(University of Pisa), Masashi Hirooka(Ehime University), Takaaki Tanaka(Okayama University), Kazuto Tajiri(Toyama University Hospital), Toshifumi Tada(Himeji Red Cross Hospital), Akemi Tsutsui(Kagawa Prefectural Central Hospital), Toru Ishikawa(Saiseikai Niigata Daini Hospital), Kouji Joko(Matsuyama Red Cross Hospital), Masanori Atsukawa(Nippon Medical School), Hideki Iwamoto, Massimo Iavarone(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Marianna Silletta(Università Campus Bio-Medico), Koichi Takaguchi(Kagawa Prefectural Central Hospital), Michitaka Imai(Saiseikai Niigata Daini Hospital), Yohei Koizumi(Ehime University), Takashi Niizeki(Kurume University), Satoshi Yasuda(Ogaki Municipal Hospital), Taeang Arai(Nippon Medical School), Noritomo Shimada(Otemae Hospital), Shinichiro Nakamura(Himeji Red Cross Hospital), Francesco Giuseppe Foschi, Kunihiko Tsuji(Teine Keijinkai Hospital), Hideko Ohama(Osaka Medical and Pharmaceutical University)
Cited by 25
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
|Journal of Clinical Oncology|2007|1.2k